Greg Hoffman is the Chief Scientific Officer at Deep Genomics, leading the team responsible for generating rich data sets to train and validate our AI platform by applying state of the art capabilities in cell biology, molecular biology, robotics, screening, and animal models.  Greg and his team play a key strategic role collaborating with our internal machine learning team and external partners to identify novel applications of our AI platform to address key unmet needs in target discovery and therapeutics development for RNA-biology.

Greg brings over 20 years of experience in the biotechnology and pharmaceutical sector, including leadership roles at Arbor Biotechnology, Obsidian Therapeutics, Sana Biotechnology, and Novartis.  Greg is an experienced leader in building innovative technology platforms to uncover mechanisms of human disease and develop novel therapeutics, working at the interface of biology and computational methods in multiple disciplines including structural biology, functional genomics, gene editing, and development of cell and gene therapies.

Greg earned his BA in Biochemistry and PhD Biophysics at Cornell and completed his postdoctoral studies at Harvard Medical School where he was a Helen Hay Whitney Fellow and a LAM Foundation Fellow. 

• 

  Chief Scientific Officer in Deep Genomics

  Biotechnology Research